VAL: ValiRx plc - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

ValiRx plc

LON:VAL

SummaryFactSheetFinancial
Price
£0.00
Loss Chance
54.1%
2.24JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Biotechnology
6 / 16
Health Care
39 / 64
United Kingdom
?
649 / 877
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
AIM ImmunoTech
LON:0A4Y
0.34
$0.40
100.00%
Palatin Technologies
LON:0KF3
2.08
$14.58
100.00%
Aptamer Group PLC
LON:APTA
1.46
£0.01
100.00%
Arecor Therapeutics plc
LON:AREC
2.46
£0.66
100.00%
Avacta Group Plc
LON:AVCT
0.58
£0.79
100.00%
Jitta Factors
Growth Opportunity (42)
Recent Business Performance (67)
Financial Strength (45)
Return to Shareholders (0)
Competitive Advantage (28)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 30 days
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.24
100.00%
1.97
101.42%
3.24
122.59%
Biotechnology
0.34
100.00%
2.08
100.00%
1.46
100.00%
COMPANY DESCRIPTION
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. The company also develops and commercializes oncology assets in the veterinary market. It has an agreement with University of Dundee. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.
www.valirx.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.